Objective: The purpose of this study was to determine the association between hyperglycemia and mortality and late-onset infections (>72 h) in extremely low birth weight (ELBW) infants.
Introduction
Hyperglycemia in premature infants has been associated with increased morbidity including retinopathy of prematurity 1,2 and intra-ventricular hemorrhage. 3, 4 In infants with necrotizing enterocolitis (NEC), hyperglycemia has also been associated with increased late mortality. 5 However, studies examining the impact of hyperglycemia on infectious morbidity and mortality in low birth weight infants are sparse.
In adults, there is increasing evidence that even 'mild' or 'moderate' hyperglycemia is associated with increased morbidity and mortality. Van den Berghe et al. 6 demonstrated that a strategy of strict glycemic control with continuous insulin infusion to maintain glucose levels less than or equal to 110 mg/dl decreased mortality in patients requiring critical care for more than 5 days, particularly in patients with multiple organ failure owing to a septic focus. Other large observational cohort studies have suggested that mild or moderate hyperglycemia in traumatically injured (>135 mg/dl) 7 and cardiac surgery (>150 mg/dl) 8 patients also results in worse outcome. In very low birth weight (VLBW) and extremely low birth weight (ELBW) infants, there is a lack of consensus regarding the threshold level defining hyperglycemia and the need for treatment with insulin. Definitions have included but are not limited to blood glucose associated with X0.5% glycosuria, 3 >9.9 mmol/l (178 mg/dl) with glycosuria, 9 >8 mmol/l (144 mg/dl), 5 a single blood sugar >13.3 mmol/l (239 mg/dl) or repeated blood sugars >8.8 mmol/l (158 mg/dl) for at least 4 h, 10 and two consecutive blood sugars >12 mmol/l (>216 mg/dl) for at least 4 h. 11 The incidence of hyperglycemia in VLBW and ELBW infants also varies based on the definition used and ranges from 40 to 80%. 12, 13 Although continuous insulin infusion has been utilized safely for managing hyperglycemia in ELBW infants, 4, 10, 11, 14 the optimal glucose target has not yet been determined. Further information from observational studies regarding the association between hyperglycemia and outcome in ELBW infants is necessary before proceeding to a potential trial of conventional versus more aggressive glucose control in these infants. We therefore conducted an observational study to evaluate the association between hyperglycemia and mortality and late-onset infections in ELBW infants using data prospectively collected for a randomized trial (Morris, unpublished data).
Materials and methods
Data were prospectively collected on 213 ELBW infants enrolled at two institutions as part of a randomized trial of sterile water gavage drip versus routine fluid administration in ELBW infants. This analysis was performed as a retrospective observational study, undertaken as a subset of the larger completed prospective clinical trial (Morris et al., personal communication). The original prospective study was conducted at two centers, Memorial Hermann Children's Hospital and Lyndon Baines Johnson (LBJ) General Hospital in Houston, TX, USA; randomization was stratified by center. Infants were eligible for the trial if they met the following criteria: (1) <31 weeks gestation by Ballard examination, (2) birth weights X400 and p1000 grams and (3) enrollment before 36 h of age. Infants were excluded if they had (1) severe asphyxia (defined as an initial infant pH<7.1 and evidence of end-organ damage), (2) major congenital anomalies, (3) hypotension treated with dobutamine or dopamine at greater than 15 mg/kg/minute or (4) anticipated death (pH<6.80 or hypoxia with bradycardia for >2 h). These infants were excluded given their poor prognosis. Infants were enrolled between March 2000 and November 2003. There were 180 infants who were eligible but not enrolled owing to the following reasons: parental refusal (54%), consent not requested (33%) and other (12%). A total of 12 infants were excluded from the analysis -11 infants were enrolled in the trial but did not survive more than 3 days of age and one infant who transferred at 3 days of age did not have available outcome data. Data collection was approved by the Institutional Review Board at University of Texas Health Science Center, and informed consent was obtained from the parents before participation in the study.
The main predictor variables of interest were mean morning glucose levels over the first 3 and 7 days after birth. In order to ensure consistent sampling among subjects, only morning glucose levels were analyzed. Inclusion of all serum laboratory values could increase the potential for confounding by severity of illness as sicker infants have their laboratory tests drawn more frequently, which increases the likelihood of identifying extreme values. Therefore, serum electrolytes and serum glucose levels were measured daily after enrollment at approximately the same time each day (around 0400 hours). The mean glucose levels were divided into the following categories: normoglycemia (<120 mg/ dl), mild-moderate hyperglycemia (120 to 179 mg/dl) and severe hyperglycemia (X180 mg/dl).
Confounding variables analyzed included: gestational age, gender, race, birth weight, use of antenatal steroids and Apgar scores at 1 and 5 min. Gestational age was estimated using the modified Ballard test because of the unreliability of using dates given that many of the women at LBJ General Hospital had no prenatal care. Outcome measures included: development of systemic infection (positive blood culture at >3 and 7 days of life treated with >3 days antibiotics), NEC (XBell's Stage II), length of stay and death before discharge. Infections that occurred before 72 h of age were excluded so as to exclude early infection, which may be more reflective of a congenital infection 15 and would be unlikely to be prevented by improved glycemic control after birth.
The primary outcome measure was a composite outcome of either mortality or late-onset culture-proven infection after 3 days and after 1 week of age. As there is no consensus on the cutoff for defining late-onset infection and given that there is no prior data regarding duration of hyperglycemia and outcome in ELBW infants, outcome at both time points was analyzed in this study. Secondary outcome measures were incidence of hypoglycemia (<40 mg/dl), development of NEC, total number of days of mechanical ventilation among survivors and length of stay for survivors not transferred to another facility.
Descriptive statistics were utilized to describe the demographic data. Univariate analyses were performed to assess the association between risk factors, including hyperglycemia, and mortality, late culture-proven infection and length of stay. For the primary outcome measure, w 2 or Fisher's exact test was utilized for categorical independent variables, and the Mann-Whitney U test or univariate logistic regression was used for continuous independent variables. For length of mechanical ventilation and length of stay, linear regression was used. Multivariate logistic and linear regression analyses were performed for categorical and continuous outcome measures, respectively. Factors that had a P-value of less than or equal to 0.25 and known risk factors based on the literature were included in the initial multivariate analyses. Because birth weight and age by Ballard exam were correlated, the variable with the strongest relationship with the outcome was included where applicable. All of the final reduced models included mean glucose categories as the independent variable of interest. Hierarchical forward selection with switching, with a maximum of four variables, was used to select the other independent variables included in the reduced models. Significance in the multivariate model was based on the Wald and deviance tests, Pp0.05. All statistical analyses were performed using Number Cruncher Statistical Systems (NCSS, 2004, Kaysville, UT, USA).
Results

Demographic data
The baseline characteristics of the 201 ELBW infants included in the study are listed in Table 1 . The majority of infants had at least two morning glucose measurements for the first 3 days of age (193/201, 96%), but eight infants whose initial serum chemistries were not drawn until after 52 h of age only had one blood glucose measurement. The median value for mean morning glucose level for the first 3 days after birth was 105 mg/dl (interquartile range (IQR): 81 to 133 mg/dl) and the average was 114±53 mg/dl. Sixtyfive percent of the infants had an average glucose level less than 120 mg/dl, 28% in the mild-moderate range and 7% in the severe range. The median value for mean morning glucose level for the first week after birth was 113 mg/dl (IQR, 97 to 132 mg/dl). Figure 1 illustrates the trend for the mean daily glucose level over time for each category of infants (normoglycemic, mildly hyperglycemic and severely hyperglycemic infants). Sixty-one percent of infants had a mean glucose in the normal range for the first week, whereas 35 and 4% had averages that were in the mildmoderate and severe groups, respectively. Overall, 77 (38%) infants had at least one glucose measurement of 180 mg/dl or higher and 10 infants (5%) had at least one episode of hypoglycemia.
The median value for mean morning glucose for the first 3 days after birth was 104 mg/dl (93 to 110 mg/dl) for infants randomized to the control or routine fluids group (n ¼ 96) and 106 mg/dl (97 to 118 mg/dl) for infants in the sterile water gavage group (n ¼ 109). This difference was not statistically significant using the Mann-Whitney test (P ¼ 0.24). However, the median glucose level for the first week after birth was significantly higher in the control (n ¼ 94) than in the sterile water gavage group (n ¼ 104) -118 mg/dl (113 to 127 mg/dl) versus 108 mg/dl (103 to 114 mg/ dl), respectively (P ¼ 0.03). There was no statistically significant difference in distribution of mean glucose levels at either 3 or 7 days across the strata of mild, moderate and severe hyperglycemia based on group randomization.
Primary outcome
Overall, 100/201 (50%) infants experienced the primary outcome of either mortality or a late-onset infection after 3 days of age. On univariate analysis, there was a greater likelihood of having a worse outcome in infants with severe hyperglycemia when compared to normoglycemic infants with a mean glucose level less than 120 mg/dl (Table 2) , but there was no statistically significant Figure 1 The daily mean morning glucose level for the infants in each category stayed relatively stable within the normoglycemic and mildly hyperglycemic groups. The daily mean morning glucose level trended downwards in the severely hyperglycemic group, but remained above high (>180 mg/dl) even after 1 week. Hyperglycemia in ELBW infants LS Kao et al association between mild-moderate hyperglycemia and outcome. Male gender, antenatal steroids, African-American race and sterile water gavage were not significant on univariate analysis. Birth weight was associated with worse outcome but because of the correlation with gestational age, the better predictor of the two was used in the final model. After adjustment for age, severe hyperglycemia was still associated with worsened outcome (Table 2 ). For mild-moderate hyperglycemia, there was not a significant increase in odds of either having an infection or dying. The r 2 for the model including hyperglycemia as a categorical value and age was 0.59.
One hundred and ninety-eight infants survived greater than 1 week, and of those infants, 95 (48%) either died or developed a subsequent infection. Using univariate logistic regression, the odds of developing the composite outcome if the mean glucose level was greater than or equal to 180 mg/dl as compared to less than 120 mg/dl was increased significantly (Table 2) . On univariate analysis, only age and birth weight were associated with the primary outcome. Adjusting for age, neither mild-moderate hyperglycemia nor severe hyperglycemia was positively associated with the outcome. The model r 2 was 0.51.
We used the composite outcome as our primary outcome because death is a competing outcome for infection, but we also analyzed each of the components of the primary outcome separately. The overall mortality of the series was 20% (40/201). On univariate analysis, severe hyperglycemia in the first 3 days of age was significantly associated with death, but not mild-moderate hyperglycemia (Table 3) . On univariate analysis, age and birth weight were the only other factors associated with increased mortality. Adjusting for age (model r 2 0.71), severe hyperglycemia was still significantly associated with mortality (Table 3) . Of the 198 infants surviving more than 7 days, 37 (19%) subsequently died. Using univariate logistic regression analysis, the odds of dying if the infant had mild-moderate hyperglycemia during the first week after birth as compared to normoglycemia was increased, as was the odds ratio (OR) for dying if the infant had severe hyperglycemia. After adjusting for age (model r 2 0.69), the odds of dying were still significantly increased for infants with severe hyperglycemia over the first week after birth, but not for infants with mild-moderate hyperglycemia.
Seventy-six infants developed a culture-proven infection after 72 h of life, and 74 infants developed an infection greater than 1 week after birth. Neither mean glucose level in the first 3 days of life nor in the first week was predictive of infection, both on univariate analysis and adjusting for African-American race and age (Table 4) .
Secondary outcomes
Eighteen infants who survived greater than 1 week developed Stage II or III NEC. There was a significant association between a mean 7-day glucose level greater than or equal to 180 mg/dl as compared to the referent category of a mean less than 120 mg/dl and development of Stage II/ III NEC (OR: 7.40, 95% confidence interval (CI): 1.52 to 36.1). After adjusting for age and male gender, the association was still significant (OR: 9.49, 95% CI: 1.52 to 59.3). The r 2 for the model including age, gender and hyperglycemia was 0.31. For infants who subsequently developed NEC, severe persistent hyperglycemia in the first week after birth was associated with increased mortality (OR: 13.1, 95% CI: 1.20 to 143) but the sample size was very small. Among survivors, there was no correlation between mean glucose category and number of days of mechanical ventilation or length of stay in the hospital on univariate or multivariate analyses. In infants surviving longer than 1 week, the main determinants of length of stay (accounting for 45% of the variability) were a diagnosis of chronic lung disease, birth weight and male gender.
Discussion
This study demonstrates a relationship between increased mean glucose levels greater than or equal to 180 mg/dl over the first 3 days of life and worsened outcome in ELBW infants. Furthermore, both early and persistent hyperglycemia over the course of the first week of life was associated with increased odds of dying, although the CIs were wide. These results are consistent with studies in other pediatric 16, 17 and adult 6,18-20 critically ill populations. In hospitalized adults, the definition of stress hyperglycemia has been challenged over the past several years based on at least one large trial demonstrating a survival benefit to maintaining a glucose target of less than 110 mg/dl in the intensive care unit (ICU). 6 However, there is a paucity of literature regarding the impact of 'mild' or 'moderate' hyperglycemia on outcome in pediatric populations. In a retrospective review of 932 patients, Faustino and Apkon 16 reported a significantly increased risk of death in non-diabetic children with elevated glucose levels above 150 mg/dl, in the first 24 h of admission (relative risk (RR): 2.50, 95% CI: 1.26 to 4.93). For children with maximum glucose levels of 120 mg/l, there may also have been an increased risk of mortality (RR: 2.10, 95% CI: 0.89 to 5.00). Srinivasan et al. 17 reported an association between peak blood glucose level (OR: 1.01, 95% CI: 1.00 to 1.02 for each mg/dl increase) and duration of hyperglycemia defined as percentage of days with blood glucose greater than 126 mg/dl (OR: 1.03, 95% CI: 1.01 to 1.05) with mortality in a cohort of 152 pediatric ICU patients. The results from this study in ELBW infants did not demonstrate a statistically significant increase in the risk of dying with mild-moderate hyperglycemia after birth. However, the small number of infants in this category who had the outcomes of interest may have reduced the power of the study to detect a difference. Likewise, further stratification of mean glucose levels, particularly between 120 and 180 mg/dl, was also limited by sample size considerations.
Although the results of this study did not demonstrate an association between early or persistent hyperglycemia and culture-proven infection, one mechanism by which strict glycemic control has been postulated to impact outcome is by decreasing the risk of septic complications. Hyperglycemia has been previously linked in animal and human studies to alterations in the immune response owing to modulation of both pro-and anti-inflammatory cytokines, [21] [22] [23] [24] [25] impairment of the neutrophil response 26 and depression of cell-mediated immunity. 27 Clinically, elevated glucose levels have been associated with increased risk of infectious complications, particularly after surgery, 8, 28 and improved glycemic control has been associated with a reduction in surgical site 8 and bloodstream infections. 6 In our study, there did not appear to be a correlation between hyperglycemia and development of a cultureproven infection after either 3 or 7 days among survivors. Owing to the small and unbalanced sample size, the study may have been underpowered to detect a small difference in the rates of infection. For example, there was only a 5% difference in infection rates after 3 days between the infants with early severe hyperglycemia and normoglycemic infants (43% or 49/130 versus 38% or 6/14) .
This study demonstrated an association between severe persistent hyperglycemia over the first week of life and Stage II/III NEC. In a retrospective study of premature infants with NEC, 69% of infants (n ¼ 95) were hyperglycemic above 144 mg/dl (8 mmol/dl) at some stage during their admission. Their mean birth weight was 1310 g and mean gestational age was 29 weeks. In this population, a maximum blood glucose level above 215 mg/dl (11.9 mmol/dl) during an ICU admission was associated with an increased risk of death (33 versus 18%, P ¼ 0.13), particularly in the subgroup of neonates who died after 10 days in the ICU (29 versus 2%, P ¼ 0.0009). 5 In our study, 75% of ELBW infants who subsequently developed NEC were hyperglycemic above 144 mg/dl within the first week after birth. Their mean birth weight was 713 g and mean gestational age was 26 weeks. Data were not collected regarding their glucose levels for the entire length of ICU stay. Nonetheless, severe persistent hyperglycemia over the first week after birth was associated with increased mortality. One limitation however of retrospective cohort studies is that causal relationships cannot be defined, but one possibility is that the more severely ill infants had a higher likelihood of both developing NEC and becoming hyperglycemic.
This study is limited by all of the inherent biases of a retrospective analysis. Although the data were originally collected for a randomized trial of sterile water gavage versus routine fluid administration in ELBW infants, the group assignment did not have any effect on either univariate or multivariate analysis on outcome. Furthermore, although the control group had a higher mean morning glucose level than the gavage group, the classification of infants by strata was not significantly different. Lastly, one advantage of using these data is the rigor in planning and data collection as a result of the randomized study design.
Another significant limitation of this study is the potential identification of a statistically significant correlation between hyperglycemia and outcome in the absence of a true causal relationship. Furthermore, even if a true correlation exists, as would be supported by prospective studies in other populations, this study does not elucidate the nature of the relationship -that is, whether hyperglycemia contributes to increased mortality or whether infants who are more severely ill are more likely to be hyperglycemic. Additionally, because of the retrospective nature of the study, we were unable to adjust for all of the potential confounders such as administration of total parenteral nutrition, insulin administration and glucose load, which were not standardized among neonatologists. However, the results of this study are in concordance with those demonstrating worse outcome with hyperglycemia in other patient populations and at the very least warrant further investigation.
In conclusion, severe hyperglycemia is associated with worsened outcome in ELBW infants. Further studies to elucidate the specific relationship between hyperglycemia, particularly in the mildmoderate range and outcome and to evaluate the effects of improved glycemic control in this patient population are necessary.
